What is Leerink Partnrs’ Forecast for ARCT FY2024 Earnings?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for Arcturus Therapeutics in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo now forecasts that the biotechnology company will post earnings of ($2.55) per share for the year, up from their prior forecast of ($3.00). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.80) EPS and Q4 2025 earnings at ($0.79) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the prior year, the firm earned ($0.61) earnings per share.

Several other research firms also recently commented on ARCT. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $66.75.

Arcturus Therapeutics Stock Up 4.1 %

NASDAQ:ARCT opened at $17.42 on Friday. The company has a market capitalization of $471.91 million, a P/E ratio of -7.85 and a beta of 2.63. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The stock’s fifty day moving average is $17.27 and its two-hundred day moving average is $19.74.

Institutional Trading of Arcturus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Arcturus Therapeutics by 10.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 846 shares during the last quarter. nVerses Capital LLC bought a new position in Arcturus Therapeutics during the 3rd quarter worth $42,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares during the period. Nordea Investment Management AB raised its holdings in shares of Arcturus Therapeutics by 3.7% during the fourth quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 2,335 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after purchasing an additional 3,224 shares during the period. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.